Clinical review report: Glucagon nasal powder (Baqsimi) (Eli Lilly Canada Inc) indication: for the treatment of severe hypoglycemic reactions which may occur in the management of insulin treated patients with diabetes mellitus, when impaired consciousness precludes oral carbohydrates

The objective of this review was to perform a systematic review of the beneficial and harmful effects of glucagon nasal powder (Baqsimi) for the treatment of severe hypoglycemic reactions which may occur in the management of insulin-treated patients with diabetes mellitus, when impaired consciousnes...

Full description

Bibliographic Details

Corporate Author:	Canadian Agency for Drugs and Technologies in Health
Format:	eBook
Language:	English
Published:	Ottawa (ON) CADTH March 2020, 2020
Edition:	Final (with redactions)
Series:	CADTH common drug review
Online Access:	https://www.ncbi.nlm.nih.gov/books/NBK562995
Collection:	National Center for Biotechnology Information - Collection details see MPG.ReNa